Thursday, April 2, 2020

Tag: AST-OPC1

A Year Ago He Was Paralyzed From the Neck Down — Then This Happened

Published: August 24, 2017 | Spinal Cord Injury: , , ,

You might feel a bit down if you watch the news. Who wouldn’t?

Angry people might be grabbing headlines and making you wonder about the future, but the antidote is all around you.

Talk to some of your neighbors. Chances are, no matter what they look like or where they’re originally from, you’ll find they’re actually pretty decent people — just like you.

The little improvements we all try to make may not register much, but the accumulation of them all eventually does.

Asterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study

Published: July 10, 2017 | Spinal Cord Injury:

Ability to enroll patients with second most common cervical spinal cord injury broadens eligible population for SCiStar study and future trials

FREMONT, Calif., July 10, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s amendment to the clinical research protocol for its ongoing AST-OPC1 SCiStar Phase 1/2a clinical trial in motor complete cervical spinal cord injury (SCI). The amendment expands the eligibility criteria to include patients with a C-4 spinal cord injury and extends the dosing window from 14 to 30 days to 21 to 42 days post-injury.

Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at...

Published: June 13, 2017

Third patient recovers two motor levels; three of six (50%) patients in AIS-A 10 million cell cohort have now recovered two motor levels on at least one side

FREMONT, Calif., June 13, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that new 9-month follow-up data from the AIS-A 10 million cell cohort in the company’s ongoing SCiStar Phase 1/2a clinical trial shows three of six (50%) patients have now recovered two levels of motor function and previously-announced improvements in arm, hand and finger function at 3-months and 6-months following administration of AST-OPC1 have been confirmed and further increased at 9-months.

Generating improvement in spinal cord injuries

Published: January 24, 2017

Early clinical trial results announced offer new hope in regenerative medicine

A new therapy to treat spinal cord injuries in people who have lost all motor and sensory function below the injury site shows additional motor function improvement at 6-months and 9-months following treatment with 10 million AST-OPC1. The positive efficacy results from an ongoing research study were announced on Jan. 24 in a conference held by Asterias Biotherapeutics, Inc., the biotechnology company that manufactures AST-OPC1.

Paralyzed Man Regains Use of Arms and Hands After Experimental Stem Cell Therapy at...

Published: September 7, 2016 | Spinal Cord Injury:

neurosurgery-stem-cell-spine-patient-kris-boesenInitial Results Offer Hope for Patients to Reclaim Independence After Suffering Severe Spinal Injury

LOS ANGELES, Sept. 7, 2016 /PRNewswire/ — Keck Medical Center of USC today announced that a team of doctors became the first in California to inject an experimental treatment made from stem cells, AST-OPC1, into the damaged cervical spine of a recently paralyzed 21-year-old man as part of a multi-center clinical trial.

Stem Cell Agency Spinal Cord Injury Clinical Trial Passes Safety Hurdles

Published: August 31, 2016 | Spinal Cord Injury: , ,

logo-CIRMOakland, CA – A clinical trial using stem cells to treat people with recent spinal cord injuries has cleared two key safety hurdles, and been given approval to expand the therapy to a larger group of patients with a much higher dose of cells.

Asterias Biotherapeutics announced that its Data Monitoring Committee (DMC) has reviewed the safety data from the first two groups of patients treated and found no problems or adverse side effects. One group of three patients was given 2 million cells. The second group of five patients received 10 million cells. Asterias is now cleared to enroll another 5-8 patients with 20 million cells.

Stem Cells vs. Spinal Cord Injuries

Published: March 22, 2016

Richard G FesslerA paralyzing injury to the neck during recreational activities such as horseback riding or playing football usually has permanent, lifelong effects that change a person’s life dramatically. With no options for the repair of spinal cord injuries, many are left with little hope for recovery.

Now researchers at Rush are exploring a new therapy that uses stem cells to treat spinal cord injuries within the first 14 to 30 days of injury. Rush is one of only two centers in the country currently studying this new approach.

Asterias begins enrollment for AST-OPC1 Phase 1/2a trial to treat complete cervical spinal cord...

Published: March 5, 2015

ast_opc1Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one of the nation’s top rehabilitation hospitals for spinal cord injury and brain injury, has commenced enrollment for the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI).

The Phase 1/2a trial follows the successful completion of the Phase 1 trial of AST-OPC1, which met its primary endpoints of safety and feasibility when administered to five patients with neurologically complete, thoracic SCI.

Do NOT follow this link or you will be banned from the site!